Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of YG1699 in Healthy Subjects
NCT03953092Phase 1Completed
- Sponsor
- Youngene Therapeutics
- Start
- May 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of YG1699 in type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus (T1D) (9 arms), sponsored by Youngene Therapeutics. Primary endpoint: Adverse events at 76 Days. Started May 2019; status: completed.
02
Drugs
YG1699
03
Conditions
type 2 diabetes mellitus (T2DM)type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03953092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953092.